<p>Zimmer Biomet Holdings, Inc. (NYSE:ZBH - 获取免费报告) 的股票在周二的午盘交易中达到了新的 52 周低点。该股最低交易价格为 97.51 美元，最后交易价格为 97.68 美元，成交量为 1152129 股。该股此前收盘价为 101.97 美元。</p>
<p>获取 <strong>Zimmer Biomet</strong> 警报：</p>
<h2>分析师升级和降级</h2>
<ul>
<li>Intuitive Surgical 在机器人手术创新中领先</li>
</ul>
<p>ZBH 最近成为多份研究报告的主题。JMP Securities 在 2 月 7 日的研究报告中重申了对 Zimmer Biomet 的 “市场表现优于大盘” 评级，并设定了 140.00 美元的目标价。摩根大通将 Zimmer Biomet 的评级从 “中性” 上调至 “增持”，并在 12 月 17 日的研究报告中将其目标价从 125.00 美元上调至 128.00 美元。巴克莱在 2 月 10 日的研究报告中将 Zimmer Biomet 的目标价从 118.00 美元下调至 112.00 美元，并对该股设定了 “减持” 评级。Truist Financial 在 2 月 10 日的报告中重申了 “持有” 评级，并将 Zimmer Biomet 的目标价设定为 113.00 美元（此前为 118.00 美元）。最后，BTIG Research 在周一的研究报告中重申了对 Zimmer Biomet 的 “买入” 评级。两位投资分析师对该股给予了卖出评级，十一位给予了持有评级，九位给予了买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，平均目标价为 124.15 美元。</p>
<p><strong>查看我们最新的 ZBH 股票报告</strong></p>
<h2>Zimmer Biomet 价格表现</h2>
<ul>
<li>2 家机器人手术公司挑战 Intuitive Surgical 的领先地位</li>
</ul>
<p>该股市值为 193.5 亿美元，市盈率为 21.85，市盈增长比率为 1.95，贝塔值为 0.84。该公司的 50 日移动平均价格为 106.19 美元，200 日移动平均价格为 106.99 美元。公司的债务股本比率为 0.43，速动比率为 0.99，流动比率为 1.91。</p>
<p>Zimmer Biomet (NYSE:ZBH - 获取免费报告) 最近在 2 月 6 日发布了其财报。该医疗设备提供商报告本季度每股收益为 2.31 美元，超出分析师一致预期的 2.30 美元，超出 0.01 美元。Zimmer Biomet 的净利润率为 11.77%，股本回报率为 12.99%。在去年同期，该公司每股收益为 2.20 美元。分析师预计 Zimmer Biomet Holdings, Inc.今年的每股收益将达到 8.22 美元。</p>
<h2>Zimmer Biomet 宣布分红</h2>
<ul>
<li>波士顿科学：为什么这家医疗科技巨头不会放慢脚步</li>
</ul>
<p>该公司还最近宣布了一项季度分红，将于 4 月 30 日支付。3 月 31 日的登记投资者将获得 0.24 美元的分红。该分红的除息日为 3 月 31 日。这代表着每年 0.96 美元的分红和 0.99% 的分红收益率。Zimmer Biomet 的派息比率目前为 21.57%。</p>
<h2>内部活动</h2>
<p>在其他消息中，SVP Lori Winkler 在 3 月 5 日的交易中出售了 1443 股 Zimmer Biomet 股票。股票以 104.40 美元的平均价格出售，总交易额为 150,649.20 美元。交易后，这位高级副总裁现在持有该公司 8768 股股票，价值 915,379.20 美元。此次交易代表其持股减少了 14.13%。该出售在向 SEC 的法律文件中披露，文件可通过此链接获取。内部人士持有该公司 0.95% 的股票。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者最近对该股的持仓进行了调整。Roman Butler Fullerton &amp; Co.在第四季度购买了 Zimmer Biomet 的新股份，价值 473,000 美元。KLCM Advisors Inc.在第四季度购买了约 7,825,000 美元的 Zimmer Biomet 新股份。Peddock Capital Advisors LLC 在第四季度购买了约 654,000 美元的 Zimmer Biomet 新股份。Van ECK Associates Corp 在第四季度将其在 Zimmer Biomet 的持股增加了 5.9%。Van ECK Associates Corp 现在拥有 3955449 股该医疗设备提供商的股票，价值 417,814,000 美元，此前在上个季度又购买了 218,688 股。最后，Reinhart Partners LLC 在第四季度将其在 Zimmer Biomet 的持股增加了 34.4%。Reinhart Partners LLC 现在拥有 86755 股该医疗设备提供商的股票，价值 9,164,000 美元，此前在上个季度又购买了 22,220 股。机构投资者持有该公司 88.89% 的股票。</p>
<h2>Zimmer Biomet 公司简介</h2>
<p>(获取免费报告)</p>
<p>Zimmer Biomet Holdings, Inc.及其子公司在全球范围内作为一家医疗技术公司运营。该公司设计、制造和销售骨科重建产品，如膝关节和髋关节产品；S.E.T.产品，包括运动医学、生物制剂、足踝、四肢和创伤产品；颅面和胸部产品，包括面部和颅骨重建产品，以及用于固定和稳定胸部骨骼以促进心脏手术、创伤或胸部畸形后的愈合或重建的产品。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过 Zimmer Biomet</li>
<li>银行股票 - 最佳银行股票投资指南</li>
<li>小心 BigBear.ai：内部人士正在出售——你应该吗？</li>
<li>如何开始投资于便士股票</li>
<li>CrowdStrike 股票在网络威胁环境扩大的情况下值得购买</li>
<li>找到并盈利交易 52 周低点的股票</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Zimmer Biomet 吗？</h2>
<p>在考虑 Zimmer Biomet 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Zimmer Biomet 并不在名单上。</p>
<p>虽然 Zimmer Biomet 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Zimmer Biomet（纽约证券交易所代码：ZBH）股票在交易中创下 52 周新低，达到 97.51 美元，收盘价为 97.68 美元。分析师的评级不一，JMP Securities 维持 “市场跑赢大盘” 评级，目标价为 140 美元，而巴克莱将其目标价下调至 112 美元。该公司报告每股收益为 2.31 美元，略高于预期，并宣布季度股息为 0.24 美元。机构投资者持有 88.89% 的股份，最近有多家机构进行了增持。Zimmer Biomet 的市值为 193.5 亿美元，市盈率为 21.85</p>

<p>Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $97.51 and last traded at $97.68, with a volume of 1152129 shares changing hands. The stock had previously closed at $101.97.</p>
<div class="lb-trans"><p>Zimmer Biomet Holdings, Inc. (NYSE:ZBH - 获取免费报告) 的股票在周二的午盘交易中达到了新的 52 周低点。该股最低交易价格为 97.51 美元，最后交易价格为 97.68 美元，成交量为 1152129 股。该股此前收盘价为 101.97 美元。</p>
</div><p>Get <strong>Zimmer Biomet</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Zimmer Biomet</strong> 警报：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><ul>
<li>Intuitive Surgical Leads the Pack in Robotic Surgery Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>Intuitive Surgical 在机器人手术创新中领先</li>
</ul>
</div><p>ZBH has been the topic of a number of recent research reports. JMP Securities reaffirmed a &#34;market outperform&#34; rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase &amp; Co. raised Zimmer Biomet from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and lifted their price target for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Barclays reduced their price target on Zimmer Biomet from $118.00 to $112.00 and set an &#34;underweight&#34; rating on the stock in a research report on Monday, February 10th. Truist Financial restated a &#34;hold&#34; rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, BTIG Research reiterated a &#34;buy&#34; rating on shares of Zimmer Biomet in a research note on Monday. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $124.15.</p>
<div class="lb-trans"><p>ZBH 最近成为多份研究报告的主题。JMP Securities 在 2 月 7 日的研究报告中重申了对 Zimmer Biomet 的 “市场表现优于大盘” 评级，并设定了 140.00 美元的目标价。摩根大通将 Zimmer Biomet 的评级从 “中性” 上调至 “增持”，并在 12 月 17 日的研究报告中将其目标价从 125.00 美元上调至 128.00 美元。巴克莱在 2 月 10 日的研究报告中将 Zimmer Biomet 的目标价从 118.00 美元下调至 112.00 美元，并对该股设定了 “减持” 评级。Truist Financial 在 2 月 10 日的报告中重申了 “持有” 评级，并将 Zimmer Biomet 的目标价设定为 113.00 美元（此前为 118.00 美元）。最后，BTIG Research 在周一的研究报告中重申了对 Zimmer Biomet 的 “买入” 评级。两位投资分析师对该股给予了卖出评级，十一位给予了持有评级，九位给予了买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，平均目标价为 124.15 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on ZBH</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ZBH 股票报告</strong></p>
</div><h2>Zimmer Biomet Price Performance</h2>
<div class="lb-trans"><h2>Zimmer Biomet 价格表现</h2>
</div><ul>
<li>2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家机器人手术公司挑战 Intuitive Surgical 的领先地位</li>
</ul>
</div><p>The stock has a market capitalization of $19.35 billion, a P/E ratio of 21.85, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The firm has a 50-day moving average price of $106.19 and a 200 day moving average price of $106.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.</p>
<div class="lb-trans"><p>该股市值为 193.5 亿美元，市盈率为 21.85，市盈增长比率为 1.95，贝塔值为 0.84。该公司的 50 日移动平均价格为 106.19 美元，200 日移动平均价格为 106.99 美元。公司的债务股本比率为 0.43，速动比率为 0.99，流动比率为 1.91。</p>
</div><p>Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the firm posted $2.20 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.</p>
<div class="lb-trans"><p>Zimmer Biomet (NYSE:ZBH - 获取免费报告) 最近在 2 月 6 日发布了其财报。该医疗设备提供商报告本季度每股收益为 2.31 美元，超出分析师一致预期的 2.30 美元，超出 0.01 美元。Zimmer Biomet 的净利润率为 11.77%，股本回报率为 12.99%。在去年同期，该公司每股收益为 2.20 美元。分析师预计 Zimmer Biomet Holdings, Inc.今年的每股收益将达到 8.22 美元。</p>
</div><h2>Zimmer Biomet Announces Dividend</h2>
<div class="lb-trans"><h2>Zimmer Biomet 宣布分红</h2>
</div><ul>
<li>Boston Scientific: Why This MedTech Giant Isn’t Slowing Down</li>
</ul>
<div class="lb-trans"><ul>
<li>波士顿科学：为什么这家医疗科技巨头不会放慢脚步</li>
</ul>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.99%. Zimmer Biomet's payout ratio is presently 21.57%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度分红，将于 4 月 30 日支付。3 月 31 日的登记投资者将获得 0.24 美元的分红。该分红的除息日为 3 月 31 日。这代表着每年 0.96 美元的分红和 0.99% 的分红收益率。Zimmer Biomet 的派息比率目前为 21.57%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.95% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，SVP Lori Winkler 在 3 月 5 日的交易中出售了 1443 股 Zimmer Biomet 股票。股票以 104.40 美元的平均价格出售，总交易额为 150,649.20 美元。交易后，这位高级副总裁现在持有该公司 8768 股股票，价值 915,379.20 美元。此次交易代表其持股减少了 14.13%。该出售在向 SEC 的法律文件中披露，文件可通过此链接获取。内部人士持有该公司 0.95% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors have recently made changes to their positions in the stock. Roman Butler Fullerton &amp; Co. purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth $473,000. KLCM Advisors Inc. purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at about $7,825,000. Peddock Capital Advisors LLC bought a new position in shares of Zimmer Biomet in the fourth quarter worth about $654,000. Van ECK Associates Corp lifted its holdings in shares of Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after buying an additional 218,688 shares in the last quarter. Finally, Reinhart Partners LLC. boosted its holdings in shares of Zimmer Biomet by 34.4% during the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider's stock valued at $9,164,000 after purchasing an additional 22,220 shares during the last quarter. Institutional investors own 88.89% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近对该股的持仓进行了调整。Roman Butler Fullerton &amp; Co.在第四季度购买了 Zimmer Biomet 的新股份，价值 473,000 美元。KLCM Advisors Inc.在第四季度购买了约 7,825,000 美元的 Zimmer Biomet 新股份。Peddock Capital Advisors LLC 在第四季度购买了约 654,000 美元的 Zimmer Biomet 新股份。Van ECK Associates Corp 在第四季度将其在 Zimmer Biomet 的持股增加了 5.9%。Van ECK Associates Corp 现在拥有 3955449 股该医疗设备提供商的股票，价值 417,814,000 美元，此前在上个季度又购买了 218,688 股。最后，Reinhart Partners LLC 在第四季度将其在 Zimmer Biomet 的持股增加了 34.4%。Reinhart Partners LLC 现在拥有 86755 股该医疗设备提供商的股票，价值 9,164,000 美元，此前在上个季度又购买了 22,220 股。机构投资者持有该公司 88.89% 的股票。</p>
</div><h2>Zimmer Biomet Company Profile</h2>
<div class="lb-trans"><h2>Zimmer Biomet 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.</p>
<div class="lb-trans"><p>Zimmer Biomet Holdings, Inc.及其子公司在全球范围内作为一家医疗技术公司运营。该公司设计、制造和销售骨科重建产品，如膝关节和髋关节产品；S.E.T.产品，包括运动医学、生物制剂、足踝、四肢和创伤产品；颅面和胸部产品，包括面部和颅骨重建产品，以及用于固定和稳定胸部骨骼以促进心脏手术、创伤或胸部畸形后的愈合或重建的产品。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Zimmer Biomet</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>How to start investing in penny stocks</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Zimmer Biomet</li>
<li>银行股票 - 最佳银行股票投资指南</li>
<li>小心 BigBear.ai：内部人士正在出售——你应该吗？</li>
<li>如何开始投资于便士股票</li>
<li>CrowdStrike 股票在网络威胁环境扩大的情况下值得购买</li>
<li>找到并盈利交易 52 周低点的股票</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Zimmer Biomet Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Zimmer Biomet 吗？</h2>
</div><p>Before you consider Zimmer Biomet, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Zimmer Biomet 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Zimmer Biomet 并不在名单上。</p>
</div><p>While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Zimmer Biomet 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Zimmer Biomet（NYSE:ZBH）创下新的 12 个月低点 - 事情经过如下